{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:43:12Z","timestamp":1785426192989,"version":"3.56.0"},"reference-count":41,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"7","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>Background: The study aimed to assess antioxidative status using standard biochemical analyses in multiple sclerosis patients during relapse and remission. Also, to evaluate the effects of gender, drug-modified treatment and clinical characteristics of multiple sclerosis on analyzed antioxidants. Methods: The study consisted of 178 relapse-remitting multiple sclerosis patients (61 relapse\/117 remission), 93 females and 85 males, with a mean age of 40.9\u00b19.8 (average age of 40.9) and 80 matched healthy controls. Ongoing drug-modified treatment received 132 patients. The serum levels of uric acid, total bilirubin, albumin, and transferrin were analyzed in both patients and controls. Extended Disability Status Scale (EDSS), disease duration and annual relapse rate were used as clinical characteristics of multiple sclerosis. Results: The antioxidant status was decreased in multiple sclerosis patients compared to controls. There was no statistically significant difference in antioxidant levels between relapse and remission. Women had less favourable antioxidative defence than men, with lower uric acid, total bilirubin and albumin. Negative correlations were found between disease duration, uric acid, annual relapse rate and total bilirubin. The use of disease-modifying therapy increased albumin levels. Conclusion: The use of standard biochemical analyses as an antioxidant tool in patients with multiple sclerosis was evidenced in this study. The gender and clinical characteristics affected antioxidant status, highlighting the need for personalized complementary adds to antioxidative therapy in multiple sclerosis.<\/jats:p>","DOI":"10.5937\/jomb0-51901","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T03:28:03Z","timestamp":1748230083000},"page":"1413-1420","source":"Crossref","is-referenced-by-count":1,"title":["An assessment of an antioxidative status in patients with multiple sclerosis using standard biochemical analyses"],"prefix":"10.5937","volume":"44","author":[{"given":"Tamara","family":"An\u0111eli\u0107","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dt6a039","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4588-3447","authenticated-orcid":false,"given":"Ivana","family":"Stevanovi\u0107","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dt6a039","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6499-1956","authenticated-orcid":false,"given":"Mirjana","family":"Miju\u0161kovi\u0107","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dt6a039","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bratislav","family":"Dejanovi\u0107","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dt6a039","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3303-9916","authenticated-orcid":false,"given":"Milica","family":"Ninkovi\u0107","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dt6a039","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Oh J, Vidal-Jordana A, Montalban X. Multiple Sclerosis: Clinical Aspects. Curr Opin Neurol 2018; 31(6): 752-9;","DOI":"10.1097\/WCO.0000000000000622"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Obradovic D, Andjelic T, Ninkovic M, Dejanovic B, Kotur-Stevuljevic J. Superoxide dismutase (SOD), advanced oxidation protein products (AOPP), and disease-modifying treatment are related to better relapse recovery after corticosteroid treatment in multiple sclerosis. Neurol Sci 2021; 42(8): 3241-7;","DOI":"10.1007\/s10072-020-04928-y"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, et al. Relapses in multiple sclerosis: Relationship to disability. Mult Scler Relat Disord 2016; 6: 10-20;","DOI":"10.1016\/j.msard.2015.09.002"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Sladojevi} M, Nikoli} S, @ivanovi} @, Simi} S, Sakala{ L, Spasi} I, Ilin~i} B, ^abarkapa V. Determination of systemic inflammatory biomarkers in multiple sclerosis. J Med Biochem 2024; 43 (2); 257-64;","DOI":"10.5937\/jomb0-45083"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Singh A, Kukreti R, Saso L, Kukreti. S Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. Molecules 2019; 24(8): 1583.doi: 10.3390\/molecules 24081583;","DOI":"10.3390\/molecules24081583"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Lassmann H, van Horssen J. Oxidative stress and its impact on neurons and glia in multiple sclerosis lesions. Biochim Biophys Acta 2016; 1862(3): 506-10;","DOI":"10.1016\/j.bbadis.2015.09.018"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Pegoretti V, Swanson KA, Bethea JR, Probert L, Eisel ULM, Fischer R. Inflammation and Oxidative Stress in Multiple Sclerosis: Consequences for Therapy Development. Oxid Med Cell Longev 2020 12; 2020: 7191080;","DOI":"10.1155\/2020\/7191080"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Cobley JN, Fiorello ML, Bailey DM. 13 reasons why the brain is susceptible to oxidative stress. Redox Biol 2018; 15: 490-503;","DOI":"10.1016\/j.redox.2018.01.008"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Ayala A, Munoz MF, Arguelles S. Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal. Oxid Med Cell Longev. 2014: 2014: 360438;","DOI":"10.1155\/2014\/360438"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Siotto M, Filippi MM, Simonelli I, Landi D, Ghazaryan A, Vollaro S, et al. Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability. Front Neurosci 2019; 13: 86;","DOI":"10.3389\/fnins.2019.00086"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Miller ED, Dziedzic A, Saluk-Bijak J, Bijak M. A Review of Various Antioxidant Compounds and their Potential Utility as Complementary Therapy in Multiple Sclerosis. Nutrients 2019; 11(7): 1528;","DOI":"10.3390\/nu11071528"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Emamgholipour S, Hossein-Nezhad A, Sahraian MA, Askarisadr F, Ansari M. Evidence for Possible Role of Melatonin in Reducing Oxidative Stress in Multiple Sclerosis Through Its Effect on SIRT1 and Antioxidant Enzymes. Life Sci 2016; 145: 34-41;","DOI":"10.1016\/j.lfs.2015.12.014"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Miller E, Wachowicz B, Majsterek I. Advances in Antioxidative Therapy of Multiple Sclerosis. Curr Med Chem 2013; 20(37): 4720-30;","DOI":"10.2174\/09298673113209990156"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Y ang D, Su Z, Wu S, Bi Y, Li X, Li J, et al. Low antioxidant status of serum bilirubin, uric acid, albumin and creatinine in patients with myasthenia gravis. Int J Neurosci 2016; 126(12): 1120-6;","DOI":"10.3109\/00207454.2015.1134526"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69(2): 292-302;","DOI":"10.1002\/ana.22366"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol 1983; 33(11): 1444-52;","DOI":"10.1212\/WNL.33.11.1444"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 2008; 27(6): 608-19;","DOI":"10.1080\/15257770802138558"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Wang L, Hu W, Wang J, Qian W, Xiao H. Low serum uric acid levels in patients with multiple sclerosis and neuromyelitis optica: An updated meta-analysis. Mult Scler Relat Disord 2016; 9: 17-22;","DOI":"10.1016\/j.msard.2016.05.008"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Niu PP, Song B, Wang X, Xu YM. Serum Uric Acid Level and Multiple Sclerosis: A Mendelian Randomization Study. Front Genet 2020; 11: 254;","DOI":"10.3389\/fgene.2020.00254"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Moccia M, Lanzillo R, Costabile T, Russo C, Carotenuto A, Sasso G, et al. Uric Acid in Relapsing-Remitting Multiple Sclerosis: A 2-year Longitudinal Study. J Neurol 2015; 262(4): 961-7;","DOI":"10.1007\/s00415-015-7666-y"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Stocker R. Antioxidant activities of bile pigments. Antioxid Redox Signal 2004; 6(5): 841-9;","DOI":"10.1089\/1523086041797999"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Juping D, Yuan Y, Shiyong C, Jun L, Xiuxiu Z, Haijian Y, Jianfeng S, Bo S. Serum bilirubin and the risk of rheumatoid arthritis. J Clin Lab Anal 2017; 31(6): e22118;","DOI":"10.1002\/jcla.22118"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Moos T, Nielsen TR, Skjorringe T, Morgan EH. Iron Trafficking Inside the Brain. J Neurochem 2007; 103(5): 1730-40;","DOI":"10.1111\/j.1471-4159.2007.04976.x"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Dopsaj V, J Martinovic J, Dopsaj M, Stevuljevic JK, Bogavac-Stanojevic N. Gender-specific Oxidative Stress Parameters. Int J Sports Med 2011; 32(1): 14-9;","DOI":"10.1055\/s-0030-1267930"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Franco PG, Pasquini LA, Perez MJ, Rosato-Siri MV, Silvestroff L, Pasquini JM. Paving the Way for Adequate Myelination: The Contribution of galectin-3, Transferrin and Iron. FEBS Lett 2015; 589(22): 3388-95;","DOI":"10.1016\/j.febslet.2015.08.001"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Aydin O, Ellidag HY, Eren E, Kurtulus F, Y aman A, Y\u0131lmaz N. Ischemia Modified Albumin Is an Indicator of Oxidative Stress in Multiple Sclerosis. Biochem Med 2014; 24(3): 383-9;","DOI":"10.11613\/BM.2014.041"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Oliveira SR, Kallaur AP, Reiche EMV, Kaimen-Maciel DR, Panis C, Lozovoy MAB, et al. Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis. Mol Neurobiol 2017; 54(4): 2961-8;","DOI":"10.1007\/s12035-016-9860-z"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Khalil M, Riedlbauer B, Langkammer C, Enzinger C, Ropele S, Stojakovic T. Cerebrospinal fluid transferrin levels are reduced in patients with early multiple sclerosis. Mult Scler 2014; 20(12): 1569-77;","DOI":"10.1177\/1352458514530020"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Burger A, Kotze MJ, Stein DJ, van Rensburg SJ, Howells FM. The Relationship Between Measurement of in Vivo Brain Glutamate and Markers of Iron Metabolism: A Proton Magnetic Resonance Spectroscopy Study in Healthy Adults. Eur J Neurosci 2020; 51(4): 984-90;","DOI":"10.1111\/ejn.14583"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Anton FM, Garcia Puig J, Ramos T, Gonzalez P, Ordas J. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. Metabolism 1986; 35(4): 343-8;","DOI":"10.1016\/0026-0495(86)90152-6"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Naz F, Jyoti S, Rahul, Akhtar N, Siddique YH. Effect of Oral Contraceptive Pills on the Blood Serum Enzymes and DNA Damage in Lymphocytes Among Users. Indian J Clin Biochem 2016; 31(3): 294-301;","DOI":"10.1007\/s12291-015-0533-x"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Weaving G, Batstone GF, Jones RG. Age and sex variation in serum albumin concentration: an observational study. Ann Clin Biochem 2016; 53(Pt 1): 106-11;","DOI":"10.1177\/0004563215593561"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Peng F, Deng X, Yu Y, Chen X, Shen L, Zhong X, et al. Serum Bilirubin Concentrations and Multiple Sclerosis. J Clin Neurosci 2011; 18(10): 1355-9;","DOI":"10.1016\/j.jocn.2011.02.023"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Kapitulnik J. Bilirubin: An Endogenous Product of Heme Degradation with Both Cytotoxic and Cytoprotective Properties. Mol Pharmacol 2004; 66(4): 773-9;","DOI":"10.1124\/mol.104.002832"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Chen J, Tu Y, Connolly EC, Ronnett GV. Heme oxygenase-2 Protects Against Glutathione Depletion-Induced Neuronal Apoptosis Mediated by Bilirubin and Cyclic GMP. Curr Neurovasc Res 2005; 2(2): 121-31;","DOI":"10.2174\/1567202053586767"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Sotgiu S, Pugliatti M, Sanna A, Sotgiu A, Fois ML, Arru G, et al. Serum Uric Acid and Multiple Sclerosis. Neurol Sci 2002; 23(4): 183-8;","DOI":"10.1007\/s100720200059"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Guerrero AL, Gutierrez F, Iglesias F, Mart\u00edn-Polo J, Merino S, Mart\u00edn-Serradilla JI, et al. Serum uric acid levels in multiple sclerosis patients inversely correlate with disability. Neurol Sci 2011; 32(2): 347-50;","DOI":"10.1007\/s10072-011-0488-5"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Pakpoor J, Seminog OO, Ramagopalan SV, Goldacre MJ. Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies. BMC Neurol 2015; 15: 16;","DOI":"10.1186\/s12883-015-0273-9"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Chittoor G, Kent JW Jr, Almeida M, Puppala S, Farook VS, Cole SA, et al. GWAS and transcriptional analysis prioritize ITPR1 and CNTN4 for a serum uric acid 3p26 QTL in Mexican Americans. BMC Genom 2016; 17: 276;","DOI":"10.1186\/s12864-016-2594-5"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Topic A, Vasic M, Markovic B, Milinkovic N, Dincic E. The Effects of Disease-Modifying Therapies on Oxidative Stress in Patients with Relapsing-Remitting Multiple Sclerosis. Clin Neuropharmacol 2022; 45(6): 157-61;","DOI":"10.1097\/WNF.0000000000000519"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Tobore TO. Oxidative\/Nitroxidative Stress and Multiple Sclerosis. J Mol Neurosci 2021; 71(3): 506-14;","DOI":"10.1007\/s12031-020-01672-y"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Procena antioksidativnog statusa kod pacijenata sa multiplom sklerozom kori\u0161\u0111enjem standardnih biohemijskih analiza"],"language":"en","link":[{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2025\/1452-82582507413A.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:12:51Z","timestamp":1761653571000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582507413A"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-51901","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}